These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20109727)

  • 1. Molecular alterations in uterine serous carcinoma.
    Hayes MP; Ellenson LH
    Gynecol Oncol; 2010 Feb; 116(2):286-9. PubMed ID: 20109727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.
    Hayes MP; Douglas W; Ellenson LH
    Gynecol Oncol; 2009 Jun; 113(3):370-3. PubMed ID: 19272638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early stage uterine serous carcinoma: management updates and genomic advances.
    Fader AN; Santin AD; Gehrig PA
    Gynecol Oncol; 2013 Apr; 129(1):244-50. PubMed ID: 23321062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE).
    Santin AD; Bellone S; Marizzoni M; Palmieri M; Siegel ER; McKenney JK; Hennings L; Comper F; Bandiera E; Pecorelli S
    Cancer; 2007 Apr; 109(7):1312-22. PubMed ID: 17326053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma.
    Díaz-Montes TP; Ji H; Smith Sehdev AE; Zahurak ML; Kurman RJ; Armstrong DK; Bristow RE
    Gynecol Oncol; 2006 Jan; 100(1):139-44. PubMed ID: 16182348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
    Menderes G; Clark M; Santin AD
    Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.
    Shih IeM; Wang TL
    J Pathol; 2011 May; 224(1):1-4. PubMed ID: 21432855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
    Boruta DM; Gehrig PA; Groben PA; Bae-Jump V; Boggess JF; Fowler WC; Van Le L
    Cancer; 2004 Nov; 101(10):2214-21. PubMed ID: 15452833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis.
    Rabban JT; Zaloudek CJ
    Pathology; 2007 Feb; 39(1):125-33. PubMed ID: 17365828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma.
    Dainty LA; Risinger JI; Morrison C; Chandramouli GV; Bidus MA; Zahn C; Rose GS; Fowler J; Berchuck A; Maxwell GL
    Gynecol Oncol; 2007 Jun; 105(3):563-70. PubMed ID: 17400285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
    Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
    Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma.
    Jones NL; Xiu J; Reddy SK; Burke WM; Tergas AI; Wright JD; Hou JY
    Gynecol Oncol; 2015 Sep; 138(3):620-6. PubMed ID: 26123645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management of serous papillary uterine cancer.
    Schwartz PE
    Curr Opin Oncol; 2006 Sep; 18(5):494-9. PubMed ID: 16894299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
    Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
    Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
    Kelly MG; O'malley DM; Hui P; McAlpine J; Yu H; Rutherford TJ; Azodi M; Schwartz PE
    Gynecol Oncol; 2005 Sep; 98(3):353-9. PubMed ID: 16005947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updates in therapy for uterine serous carcinoma.
    Roque DM; Santin AD
    Curr Opin Obstet Gynecol; 2013 Feb; 25(1):29-37. PubMed ID: 23138439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.
    Black JD; English DP; Roque DM; Santin AD
    Womens Health (Lond); 2014 Jan; 10(1):45-57. PubMed ID: 24328598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
    Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
    Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
    Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
    Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.